Skanditeks subsidiary CMA Microdialysis AB Announces FDA Clearance.

Skanditeks subsidiary CMA Microdialysis AB Announces FDA Clearance. CMA Microdialysis AB today announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the CMA Cerebral Tissue Monitoring System. The system measures intra cranial glucose, lactate, and pyruvate levels as an adjunct monitor to indicate the perfusion status of brain tissue. This is a milestone in the history of the company as it opens one of the largest markets in the world. As to the rest, we refer to enclosed press release from CMA Microdialysis AB. Stockholm, October 29, 2002 SKANDITEK INDUSTRIFÖRVALTNING AB (publ) For further information, please contact: Patrik Tigerschiöld, president, phone +46 8 614 00 20, mobile +46 70 777 71 90, e-mail patrik.tigerschiold@skanditek.se Skanditek is an industrial holding company owning stock in Swedish unlisted and listed companies. The business concept is to be an active and long-term stockholder and to further the portfolio companies' development by providing industrial and financial competence at board and management level. The portfolio comprises 12 companies within electronics, information technology, biotechnology and services. The major holdings are in Axis (14%), LGP Telecom Holding (9%), Mydata Automation (39%), PartnerTech (40%) and Vitrolife (35%). Skanditek is listed on the Stockholm Exchange's O list. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2002/10/29/20040928BIT21750/wkr0001.pdf